Pharmacoeconomic evaluation of cefaclor in the pharyngo-tonsillitis and acute otitis in children
| Autor: | Milena Lo Giudice, Mario Eandi |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
lcsh:R5-920
Pediatrics medicine.medical_specialty economic evaluation business.industry medicine.drug_class Tonsillitis Antibiotics Cephalosporin pharyngotonsillitis (ft) oral antibiotics medicine.disease Azithromycin Otitis Clarithromycin Economic evaluation medicine medicine.symptom lcsh:Medicine (General) business Cefaclor acute otitis media (oma) medicine.drug |
| Zdroj: | Farmeconomia: Health Economics and Therapeutic Pathways, Vol 7, Iss 1, Pp 5-20 (2006) |
| ISSN: | 2240-256X |
| DOI: | 10.7175/fe.v7i1.684 |
| Popis: | Pharyngotonsillitis (FT) and acute otitis media (OMA) are among the most frequent infectious diseases of the childhood and exact a heavy toll on the Italian national health service (INHS), families and society as a whole. In case of established or suspected bacterial origin, current treatment guidelines for FT recommend 5-10 days of oral antibiotics, chosen among available penicillins, cephalosporins, or macrolides. More controversial appears the systematical use of an antibiotic for OMAs, but prevalent expert opinion suggests use of the same agents. In this paper, an economical appraisal of five of the most prescribed oral antibiotics for these indications in Italy (cefaclor, amoxicyllin, amoxicyllin/clavulanate, clarithromycin and azithromycin) is provided. The evaluation was conducted through the development and implementation of two distinct models, constructed to reflect national treatment patterns of these infections. Clinical and economical data were obtained from several sources: literature review, including published meta-analyses, consultation of an expert panel and, most importantly, from the results of a specific questionnaire-based survey completed by 136 pediatricians, based throughout Italy. The models were run to conduct both cost-effectiveness and cost-minimization analyses, that consistently indicated cefaclor and amoxicyllin to be substantially equivalent in terms of total costs to the INHS and the Italian society, but significantly more convenient than amoxicyllin/clavulanate, claritrhomycin or azithromycin. Extensive probabilistic sensitivity analyses confirmed the robustness of this conclusion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|